Title:
Allogeneic-cell medical treatment: Mirror effect
Document Type and Number:
Japanese Patent JP6030819
Kind Code:
B2
Abstract:
A method of manipulating allogeneic cells for use in allogeneic cell therapy providing a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism, or “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect The anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in a patient.
More Like This:
Inventors:
Michael Hull-Neu
Application Number:
JP2010232031A
Publication Date:
November 24, 2016
Filing Date:
October 14, 2010
Export Citation:
Assignee:
Immunative Therapy, Limited
International Classes:
A61K35/12; A61P35/00; C12N5/0783; A61K39/00
Domestic Patent References:
| JP2001528806A |
Foreign References:
| WO2003015705A1 |
Other References:
Journal of Immunotherapy,2001,Vol.24,No.5,p.408-419
Journal of Pharmaceutical Sciences,1998,Vol.87,No.11,p.1375-1378
Journal of Pharmaceutical Sciences,1998,Vol.87,No.11,p.1375-1378
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Natsuki Morishita